MS treatment access: what really gets in the way?
NCT ID NCT07710105
First seen Jul 17, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study looks at why some people with multiple sclerosis (MS) start or stay on Ocrevus Zunovo, a high-efficacy therapy, while others do not. Researchers will survey and interview 150 MS patients, along with their families and healthcare providers, to identify barriers and facilitators to treatment. The goal is to find ways to improve access to effective MS therapies in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Simple chin and neck exercises put to the test for MS swallowing problems
- Could a daily walk shield the brain's wiring in aging MS patients?
- Brain boot camp: can a memory-training program sharpen thinking in multiple sclerosis?
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Brain training without drugs: can imagining movement ease MS pain?